CHI’S Pharmacogenomics Now: Maximizing Benefits/Minimizing Risk

5 - 6 November 2008, Montreal, Quebec, Canada

Introduction

Pharmacogenomics is being implemented now and is already have an impact in the clinical setting and in healthcare. Employing a pharmacogenomics strategy with marketed drugs can mitigate risk by avoiding adverse events, allowing the identification of patients most likely to benefit from a drug, and thereby improving patient compliance and safety. Tangible benefits of pharmacogenomics and resequencing technologies will be presented, and the value of this approach will be demonstrated.

Venue